Treatment of Neuroendocrine Tumors (NETs) with combination of Everolimus and Radiolabeld Somatostatin Analogue Read more about Treatment of Neuroendocrine Tumors (NETs) with combination of Everolimus and Radiolabeld Somatostatin Analogue
Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes Read more about Potential Benefits of Black Seed Oil Supplementation on Asthma Inflammation and Outcomes
Effect of Gum Arabic supplementation on butyrate, uremic retention molecules and inflammation in chronic kidney disease patients Read more about Effect of Gum Arabic supplementation on butyrate, uremic retention molecules and inflammation in chronic kidney disease patients
A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP). Read more about A randomized, double-blind, placebo-controlled phase II study to investigate the efficacy and safety of riociguat (0.5 mg, 1.0 mg, 1.5 mg, 2.0 mg and 2.5 mg TID) in patients with symptomatic pulmonary hypertension associated with idiopathic interstitial pneumonias (IIP).
Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial Read more about Postoperative Analgesic Effect ofDexmedetomidine as an Adjunct to Ropivacaine Administration in Wound Infiltration for Modified Radical Mastectomy- A Randomized controlled Trial
An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE). Read more about An Open-lable, Multicenter, Phase 2 Study to Evaluate Everolimus as Monotherapy Treatment for patients with Metastatic Recurrent and/or Unresectable Renall Cell Carcinoma (EVERMORE).
A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet) Read more about A Randomized, Open-label, Multicentral, Two Arm, Phase II Study to Investigate the Benefits of an Improved Deferasirox Formulation (Film-coated Tablet)
Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS Read more about Phase 2, Single-Site, Open-Label, Randomized, 2-ArmParallel Study to Assess the Efficacy and Safety ofRyanodex® (EGL-4104) as Adjuvant Treatment inSubjects With Exertional Heat Stroke (EHS
An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency Read more about An Open Label, Multicenter, Dose Escalation Study to Evaluate the Safety, Tolerability, Efficacy, Pharmacokinetics, and Pharmacodynamics of SBC-102 (Sebelipase Alfa) in Children With Growth Failure Due to Lysosomal Acid Lipase Deficiency
An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP). Read more about An Open-Label, Multicenter, Multinational Study of the Safety, Efficacy and Pharmacokinetics of Asfotase Alfa (human recombinant tissue non-specific alkaline phosphatase fusion protein) in Infants and Children ≤ 5 Years of Age with Hypophosphatasia (HPP).